Jiangsu Jingze Biomedical

Jiangsu Jingze Biomedical is a clinical-stage biotechnology company headquartered in Taizhou, China, dedicated to the development of biosimilars and innovative biologics. The company's primary therapeutic focus lies in ophthalmology, metabolic diseases, and oncology, addressing significant unmet medical needs in the Chinese market. Its advanced pipeline includes several late-stage candidates, most notably biosimilars for aflibercept and ranibizumab, which are currently in Phase 3 clinical trials for retinal diseases. Jingze Biomedical leverages its integrated R&D and large-scale GMP manufacturing capabilities to ensure the high quality and cost-effectiveness of its protein-based therapeutics. By combining a robust technical platform with a strategic focus on high-growth therapeutic areas, the company aims to become a leading provider of affordable biopharmaceuticals.